Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Curcumin phytosome (e.g., Meriva) is a phosphatidylcholine complex that significantly increases curcumin bioavailability compared to standard turmeric extract. Its safety profile mirrors curcumin but with potentially greater systemic exposure. GI discomfort at high doses is the main side effect. The increased bioavailability may amplify interactions with CYP3A4-metabolised drugs including anticoagulants. Use with caution in patients on warfarin, chemotherapy, or immunosuppressants.
Biological and Chemical Classification
- Scientific Name
- Curcuma longa
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Curcumin Phytosome indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:07
Evidence Distribution
-
Observational / other LOW evidence YELLOWOptimization of the extraction of Curcuma longa L. oleoresin with supercritical CO2. ↗Barriga-Su00e1nchez M et al.. Optimization of the extraction of Curcuma longa L. oleoresin with supercritical CO2.. An Acad Bras Cienc. 2026. PMID:41880396.PMID 41880396 ↗Journal An Acad Bras CiencYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41880396/
-
Observational / other LOW evidence YELLOWCurcumin in Behu00e7et's disease: exploring therapeutic potential, evidence, and key research gaps. ↗Heidari Z et al.. Curcumin in Behu00e7et's disease: exploring therapeutic potential, evidence, and key research gaps.. Inflammopharmacology. 2026. PMID:41879901.PMID 41879901 ↗Journal InflammopharmacologyYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41879901/
-
Observational / other LOW evidence YELLOWCurcumin Nanocrystals: Synthesis, Optimisation and Prospects of Anticancer Activity Against Primarily Female-Associated Cancers. ↗Ndongwe T et al.. Curcumin Nanocrystals: Synthesis, Optimisation and Prospects of Anticancer Activity Against Primarily Female-Associated Cancers.. Int J Nanomedicine. 2026. PMID:41878136.PMID 41878136 ↗Journal Int J NanomedicineYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41878136/
-
Observational / other LOW evidence YELLOWCurcumin: A Multifunctional Molecule for the Detection of Various Adulterants, Pathogens, and Toxins in the Agro-Food Industry. ↗Gupta KK et al.. Curcumin: A Multifunctional Molecule for the Detection of Various Adulterants, Pathogens, and Toxins in the Agro-Food Industry.. Compr Rev Food Sci Food Saf. 2026. PMID:41877454.PMID 41877454 ↗Journal Compr Rev Food Sci Food SafYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41877454/
-
Observational / other LOW evidence YELLOWCHARMM Force Field for Curcuma longa Phytochemicals: Towards Reliable Modeling of Curcuminoids and Turmerones in Biological Systems. ↗Archana et al.. CHARMM Force Field for Curcuma longa Phytochemicals: Towards Reliable Modeling of Curcuminoids and Turmerones in Biological Systems.. J Comput Chem. 2026. PMID:41858136.PMID 41858136 ↗Journal J Comput ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41858136/
-
Observational / other LOW evidence YELLOWCurcuma longa-derived extracellular vesicle-like particles ameliorate retinal neovascularization through HIF-1u03b1 and NRF2 signaling. ↗Chen Y et al.. Curcuma longa-derived extracellular vesicle-like particles ameliorate retinal neovascularization through HIF-1u03b1 and NRF2 signaling.. J Nanobiotechnology. 2026. PMID:41851718.PMID 41851718 ↗Journal J NanobiotechnologyYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41851718/
-
Observational / other LOW evidence YELLOWPhytomedicines and conventional drugs in scabies management. ↗Hoque M. Phytomedicines and conventional drugs in scabies management.. GMS Hyg Infect Control. 2026. PMID:41835968.PMID 41835968 ↗Journal GMS Hyg Infect ControlYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41835968/
-
Observational / other LOW evidence YELLOWIntegrated In silico and In vitro Screening of Phytoconstituents as Potential Inhibitors of New Delhi Metallo-u03b2-lactamase-1 (NDM-1). ↗Kumar A et al.. Integrated In silico and In vitro Screening of Phytoconstituents as Potential Inhibitors of New Delhi Metallo-u03b2-lactamase-1 (NDM-1).. Curr Pharm Biotechnol. 2026. PMID:41830576.PMID 41830576 ↗Journal Curr Pharm BiotechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41830576/
-
Observational / other LOW evidence YELLOWStair-climbing resistance exercise, with or without oral turmeric (Curcuma longa L.) supplementation, relieves symptoms and promotes musculoskeletal repair in experimental rheumatoid arthritis… ↗Kuhn MG et al.. Stair-climbing resistance exercise, with or without oral turmeric (Curcuma longa L.) supplementation, relieves symptoms and promotes musculoskeletal repair in experimental rheumatoid arthritis in rats.. J Muscle Res Cell Motil. 2026. PMID:41824114.PMID 41824114 ↗Journal J Muscle Res Cell MotilYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41824114/
-
Observational / other LOW evidence YELLOWCurcumin in oral health: mechanisms, clinical evidence, and delivery strategies. ↗Hu C et al.. Curcumin in oral health: mechanisms, clinical evidence, and delivery strategies.. Front Pharmacol. 2025. PMID:41846867.PMID 41846867 ↗Journal Front PharmacolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41846867/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Curcumin Phytosome. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Curcumin Phytosome
A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.